Advanced Cardiovascular Systems, Inc.

Abbott Cardiovascular Systems, Inc.

Gina Zhang

Syed F A Hossainy

Yiwen Tang

Gordon S Stewart

Stephen D Pacetti

Lothar W Kleiner

Jessica R DesNoyer

Syed Faiyaz Ahmed Hossainy

Wouter Erik Roorda

Paul M Consigny

Gene Park

Yung-Ming Chen

Christopher Feezor

Stephen R Dugan

Nancy Kirsten

Syed Faiyaz Shmed Hossainy

Thierry Glauser

Qi S Wang

Sean A McNiven

Fuh-Wei Tang

Deborah L Kilpatrick

Jeffrey T Ellis

Andrew F McNiven

Eugene Park

Jin Cheng

Maricela Kezis

Brandon J Yoe

Syed FA Hossainy

The present disclosure teaches methods of controlling the release rate of agents from a polymeric matrix. The methods relate to the application of pressure, and optionally, in combination with heat, to a polymeric coating.

Methods of treatment of polymeric coatings for control of agent release rates

A composition including a solution suitable for introduction into a blood vessel comprising particles including a treatment agent and a tunable stimuli-responsive polymer. A method including introducing a delivery device into a blood vessel; and introducing a solution into the blood vessel, the solution including particles comprising a treatment agent and a tunable stimuli-responsive polymer. A method including combining a treatment agent and a tunable stimuli-responsive polymer; and forming particles of the combination suitable for delivery through a blood vessel.

Stimuli responsive polyester amide particles

The present invention generally encompasses a medical article, such as a medical device or coating comprising an agent or combination of agents, wherein the agent is distributed throughout a polymeric matrix. The polymeric matrix comprises an agent and a poly(ester amide) having a design that was preselected to provide a predetermined release rate of the combination of agents from the medical article.

Poly(ester amides) for the control of agent-release from polymeric compositions

A method of making a therapeutic composition, as well as the therapeutic composition so made, is disclosed. The method comprises mixing a hydrophobic drug with an aqueous buffer solution and adding a surfactant to the aqueous buffer solution to form the therapeutic composition. A implantable medical device with the therapeutic composition and a method of making a coating for an implantable medical device containing the therapeutic composition is also disclosed.

Therapeutic composition and a method of coating implantable medical devices

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders

A drug-delivery system is provided including at least 100 &#x3bc;g of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 &#x3bc;g, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device

Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

Drug-delivery stent formulations for restenosis and vulnerable plaque

Provided herein is a PEA polymer blend and coatings or implantable devices formed therefrom.

Poly(ester amide) filler blends for modulation of coating properties

Provided herein is a PEA polymer blend and coatings or implantable devices formed therefrom. The PEA polymer blend is formed of a PEA polymer and a material capable of hydrogen bonding with the PEA. The PEA polymer blend can form a coating on an implantable device, one example of which is a stent. The coating can optionally include a biobeneficial material and/or optionally with a bioactive agent. The implantable device can be used to treat or prevent a disorder such as one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

A polymeric coating for a medical device that comprises poly(lactic acid) and a block copolymer including blocks of poly(ethylene glycol) and poly(butylene terephthalate) is provided.

Growing community of inventors

Fremont, CA, United States of America

Gina Zhang